Skip to content
Screener

Crinetics Pharmaceuticals CRNX Business Segments — Total other income, net

Similar metrics at other companies

Vaxcyte, Inc. logo
PCVXReportable Segment — Total other income, net
$25.23M-37.0%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Total other income, net
$193K-87.0%
LiveRamp Holdings, Inc. logo
RAMPReportable Segment — Total other income, net
$3.09M-16.7%
Enphase Energy logo
ENPHReportable Segment — Total other income, net
$10.38M+99.7%
Prime Medicine logo
PRMEReportable Segment — Total other income, net
$1.18M+49.6%
Bicara Therapeutics logo
BCAXReportable Segment — Total other income
$4.08M-18.6%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Total research and development expenses(100,081)(76,240)
Selling, general and administrative
Other selling, general and administrative expenses (2)(20,442)(14,774)
Selling, general and administrative personnel expenses(20,037)(12,093)
Selling, general and administrative stock-based compensation(10,352)(8,659)
Total selling, general and administrative expenses(50,831)(35,526)
Total other income, net12,53314,631
Segment and consolidated net loss$(127,845)$(96,774)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's business segments — total other income, net?
Crinetics Pharmaceuticals (CRNX) reported business segments — total other income, net of $12.53M in Q1 2026.
How has Crinetics Pharmaceuticals's business segments — total other income, net changed year-over-year?
Crinetics Pharmaceuticals's business segments — total other income, net decreased by 14.3% year-over-year, from $14.63M to $12.53M.
What does business segments — total other income, net mean?
Includes non-operating income and expenses, such as interest income from cash reserves, foreign exchange gains or losses, and other miscellaneous financial items. This metric provides insight into the company's financial management outside of its core pharmaceutical research and commercial activities. It is a key component of the company's overall net financial position.

Ask your AI about Crinetics Pharmaceuticals's business segments — total other income, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude